Ixo-vec Gene Therapy Reduces Anti-VEGF Injections in nAMD

A single injection of ixoberogene soroparvovec reduced anti-VEGF injection needs by 90%-95% at 26 weeks in patients with neovascular age-related macular degeneration.
Medscape Medical News